OBJECTIVES: There is limited published evidence on demographic and vitreoretinal interface (VRI) characteristics of patients with vitreomacular traction (VMT), including when associated with macular hole (VMT+MH). Establishing insights into the characteristics of untreated VMT patients may contribute to a better understanding of the burden of VMT disease.  The objective of our analysis is to describe baseline patient characteristics and VRI features in patients with persistent VMT included in the phase 3 ocriplasmin studies. This analysis reports on VMT patients without MH (VMT) and VMT patients with MH (VMT+MH)  METHODS: Two randomized, double-masked, placebo-controlled trials designed to determine efficacy and safety of ocriplasmin for the treatment of VMT comprising of 652 patients (VMT n=499; VMT+MH n=153). Baseline characteristics included patient demographics (age, gender); eye-disorder characteristics (time since diagnosis, visual acuity (VA) in study eye (SE); VA in non-study eye (NSE), presence of pseudophakia and/or ERM; VRI features (focal adhesion ≤1500 microns; min-max MH width), VFQ-25 composite score RESULTS: Baseline characteristics for VMT vs. VMT+MH patients were respectively: 72.6 vs. 68.7 years; 62.7% vs. 75.8% female. Time since diagnosis: 268 days vs. 62 days; VA: SE 66.8 vs. 55.9, NSE 73.5 vs. 77.8. Pseudophakes: 38.7% vs. 20.9%, concomitant ERM: 46.3 % vs. 15.8%. The majority of VMT patients presented with focal adhesion ≤1500 microns (69%) while VMT+MH patients presented with a min-max hole width of 272.7 microns. VFQ-25 composite score: 78.0 vs. 80.3. CONCLUSIONS: Baseline characteristics of the MIVI-TRUST ocriplasmin patient population show differentiations between patients with persistent VMT versus those with associated MH. This analysis establishes the representativeness of the MIVI-TRUST patient population in the context of clinical practice